Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Undergraduate School

Loyola University

Chicago, IL

Medical School

Central American Health Science University

2010, Ladyville, Belize

Residency

Penn State Health Milton S. Hershey Medical Center

2014, Hershey, PA

Fellowship

Penn State Health Milton S. Hershey Medical Center

2017, Hershey, PA

Fellowship

Bone Marrow Transplant

Cancer and Blood Diseases Institute at Cincinnati Children's Hospital

2019, Cincinnati, OH

Certifications

  • American Board of Pediatrics (General)
  • American Board of Pediatrics (Hematology-Oncology)

Professional History

Dr. Kapadia grew up in the suburbs of Chicago and completed her bachelor's from Loyola University. She went on to medical school, attending Central American Health Science University in Belize. She completed both her pediatric residency and her pediatric hematology / oncology fellowship at Penn State Health Milton S. Hershey Medical Center. There, very early in her training, she developed an interest in bone marrow transplant. As a result, she went on to complete her second fellowship in bone marrow transplantation at Cincinnati Children's Hospital.

Publications

  1. Multicenter Study on Caregiver Experiences in Pediatric Hematopoietic Stem Cell Transplantation: Part II. Treatment Challenges, Communication Barriers, and Caregiver-Driven Approaches to Mitigation. Transplant Cell Ther. 2025 May 10. View Abstract

  2. Multicenter Study on Caregiver Experiences in Pediatric Hematopoietic Stem Cell Transplantation Part I: Integrative Analysis of Mental Health, Psychosocial Stressors, and Support Mechanisms. Transplant Cell Ther. 2025 Apr 21. View Abstract

  3. Umbilical Cord Blood Reduced Relapse but Increased Nonrelapse Mortality Compared to Matched Unrelated Donor Transplantation in Pediatric Acute Myeloid Leukemia With Active Disease: A CIBMTR 2008 to 2017 Analysis of Donor Source and Residual Disease. Transplant Cell Ther. 2025 Apr; 31(4):261.e1-261.e15. View Abstract

  4. Engraft: A Collaborative Learning Health Network for Enhanced Transplant and Cellular Therapy Outcomes. Transplant Cell Ther. 2025 Mar; 31(3):123-134. View Abstract

  5. Induction of remission after donor lymphocyte infusion following allogeneic transplant in a case of pediatric primary myelofibrosis. Pediatr Blood Cancer. 2024 Oct; 71(10):e31248. View Abstract

  6. B-cell-directed CAR T-cell therapy activates CD8+ cytotoxic CARneg bystander T cells in patients and nonhuman primates. Blood. 2024 07 04; 144(1):46-60. View Abstract

  7. A Novel Combination of Compound Heterozygous Variants in IFNGR1 Causing Complete IFNGR1 Deficiency. J Clin Immunol. 2024 04 27; 44(5):111. View Abstract

  8. Relevance of lymphocyte proliferation to PHA in severe combined immunodeficiency (SCID) and T cell lymphopenia. Clin Immunol. 2024 04; 261:109942. View Abstract

  9. Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: A  Primary Immune Deficiency Treatment Consortium study. J Allergy Clin Immunol. 2024 May; 153(5):1423-1431.e2. View Abstract

  10. Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD. Blood. 2023 12 14; 142(24):2105-2118. View Abstract

  11. Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation. Clin Case Rep. 2023 Nov; 11(11):e8190. View Abstract

  12. Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study. J Allergy Clin Immunol. 2024 01; 153(1):287-296. View Abstract

  13. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. 2023 08 22; 7(16):4647-4657. View Abstract

  14. Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium. Lancet. 2023 07 08; 402(10396):129-140. View Abstract

  15. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. 2023 May 24. View Abstract

  16. The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions. J Allergy Clin Immunol. 2023 02; 151(2):547-555.e5. View Abstract

  17. Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC. Blood. 2022 08 18; 140(7):685-705. View Abstract

  18. Quality Improvement in Hematopoietic Stem Cell Transplant and Cellular Therapy: Using the Model for Improvement to impact Outcomes. Transplant Cell Ther. 2022 05; 28(5):233-241. View Abstract

  19. Safety of Surgical Fertility Preservation Procedures in Children Prior to Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2021 08; 27(8):696.e1-696.e4. View Abstract
BESbswy